Premium
Castration remains despite decreasing definitive treatment of localized prostate cancer in the elderly: A case for de‐implementation
Author(s) -
Skolarus Ted A.,
Caram Megan EV,
Chapman Christina H.,
Smith David C.,
Hollenbeck Brent K.,
Hawley Sarah,
Tsodikov Alexander,
Sales Anne,
Wittmann Daniela,
Zaslavsky Alexander
Publication year - 2018
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.31665
Subject(s) - medicine , prostate cancer , androgen deprivation therapy , radiation therapy , cancer , castration , quality of life (healthcare) , prostate , oncology , intensive care medicine , hormone , nursing
Maximizing the quality and quantity of life among men with localized prostate cancer who are elderly and have competing comorbidities may be achieved more effectively, either by treating these patients definitively or by opting for observation rather than using primary androgen‐deprivation therapy. A better understanding of the optimal ways to de‐implement this low‐value cancer care appears to be warranted for both elderly patients, who have little to gain by it, and younger patients, who have more to lose by foregoing definitive treatment with surgery or radiation therapy.